Skip to main content
Figure 3 | Molecular Pain

Figure 3

From: Inhibition of p38-MAPK signaling pathway attenuates breast cancer induced bone pain and disease progression in a murine model of cancer-induced bone pain

Figure 3

Effects of acute administration of SB203580 (15 and 30 mg/kg, i.p.) at day 13 post-surgery on cancer-induced spontaneous flinching (A, B), spontaneous guarding (C,D) and tactile allodynia (E,F). Time-course analyses indicate a time-dependent decrease in spontaneous flinching (A) and guarding (C) but not tactile allodynia (E).#indicates significant difference from pre-drug levels, *indicates significant difference from the vehicle treated group (p < 0.05). Analysis of the peak effect (60 min post-administration, indicates decreased tumor-induced flinching at both doses (B), decreased time spent guarding at the highest dose (D) and no change in tactile hypersensitivity (F). *indicates significant difference from the vehicle treated group (p < 0.05). All graphs show means ± SEM, n = 10.

Back to article page